Disclaimer

The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR® therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe.

Contact us

BELGIUM

Headquarters

New address:
Sequana Medical NV
Kortrijksesteenweg 1112 bus 112
9051 Sint-Denijs Westrem

[Previous address:
Sequana Medical NV
AA Tower
Technologiepark-Zwijnaarde 122
9052 Ghent]

  • +32 9 298 2828

SWITZERLAND

Swiss Authorized Representative (CH-REP)

Sequana Medical NV
Technoparkstrasse 1
Building Darwin, 2nd floor
8005 Zurich

  • +41 44 403 55 00

GERMANY

Sequana Medical GmbH
Rundfunkplatz 2
80335 München

  • +49 89 38 03 84 05

Request information

For enquiries or to request information material, please use the contact form below.

    I agree to the Sequana Medical Privacy Policy

    Customer Service numbers

    Germany
    0800 72 44 872

    United Kingdom
    0800 069 84 89

    Switzerland
    +41 44403 55 29

    We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our. Privacy & Cookie Policy

    The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

    Close